Emerging evidence showed miR499a could not only function as an oncogene but also as a tumor suppressor in various types of cancer, such as melanoma. However, whether miR499a was involved in hepatocarcinogenesis remains unknown. We previously reported that miR499a was up-regulated in HBV-mediated hepatocellular carcinoma (HCC). In this study, we found that HBV could induce the expression of miR499a by promoting its promoter activity. In addition, we reported that miR499a increased cell proliferation and cell migration of HCC cells. MAPK6 was further identified as a target of miR499a, which could also be down-regulated by HBV. Moreover, we demonstrated that MAPK6 could rescue the cell growth induced by miR499a and HBV. These findings indicated that miR499a might play an oncogene role by targeting MAPK6 in the development and progression of HBV-related HCC.
Introduction
Chronic HBV infection, which is endemic in such as South-East Asia and Sub-Saharan Africa, are greatly detrimental to human health and affect quality of life [1, 2] . Numerous studies have shown that hepatocellular carcinoma (HCC) is closely associated with Hepatitis B virus (HBV) infection [3] . However, the pathogenic mechanism of HBV-inducing HCC remains elusive.
MicroRNAs (miRNAs), one of short non-coding RNAs, play a pivotal role in negatively repression of gene expression by interacting with the 39UTR of protein-coding mRNA. Emerging evidence has demonstrated that nearly all major biological and cellular events were regulated by miRNAs [4] [5] [6] [7] [8] . The expression of miRNA also plays an important role in the carcinogenesis of HBV-induced HCC [9] . Several research found that miR499a could increase the risk of death in variety of diseases, such as acute non-ST elevation myocardial infarction, colorectal cancer and non-small cell lung cancer [10] [11] [12] . Li et al. found that miR499a regulated cell proliferation and apoptosis during late-stage cardiac differentiation [13] . Our previous research (miRNA microarray) has shown that miR499a was upregulated in HBV-related HCC cells. Whether miR499a was involved in the carcinogenesis and development of HBV-related HCC was unclear.
Mitogen-activated protein kinase(MAPK6, ERK3), a distinct MAPK subfamily, is one of atypical MAPK [14] . So far the only substrate of MAPK6 that has been identified is the MAP kinaseactivated protein kinase MK5 [15, 16] . Numerous observations announced an involvement of the ERK3/4-MK5 pathway in cell cycle regulation. Meanwhile, a recent study reported that the ERK3/4-MK5 pathway play roles in tumor promoting and suppressing [17] . Then, what's the role of MAPK6 in the process of HCC?
In this study, we mainly explored the functions of miR499a in HCC cells, as well as the molecular mechanism of miR499a inducing HCC. Firstly, the expression levels of miR499a in HBVrelated HCC cell lines were examined and the functions of miR499a were also analyzed. In addition, we explored the target gene of miR499a to disclose the underlying mechanism of miR499a functions in HCC. Our study will provide a novel pathogenic mechanism of miR499a contributing to HCC development.
Result

HBV up-regulated miR499a by increasing its promoter activity
Firstly, miR499a expression in HepG2.2.15 and HepG2 cells were analyzed by quantitative real-time PCR. Consistent with our previous miRNA microarray result, miR499a expression was significantly up-regulated in HepG2.2.15 compared with HepG2 cells (Fig. 1A) .MiR499a expression was also examined in Ad-HBV or Ad-GFP infected HepG2 cells. qRT-PCR result showed that the expression of miR499a was increased in Ad-HBV infected HepG2 cells in comparison with the control (Fig. 1B) . Meanwhile, miR499a expression was upregulated by all the four major HBV proteins, especially by HBx and HBs (Fig. 1C) .
To explore the molecular mechanism of HBV regulating miR499a expression, the miR499a promoter plasmid was respectively cotransfected with pCH9/3091 plasmid or the four major HBV proteins expression plasmids (pCMV-Sport6-HBx, pCMV-Sport6-HBs, pCMV-Sport6-HBc and pCMV-Sport6-HBp). The luciferase assay illuminated that HBV and two of its proteins (HBx and HBs) could markedly increase miR499a promoter activity (Fig. 1D) . Together, these data demonstrated that HBV could up-regulate miR499a expression by increasing its promoter activity.
MiR499a accelerated growth of HCC cells
To explore whether miR499a could affect cell proliferation of HCC cells, SMMC-7721 cells were transiently transfected with pTarget-miR499a or miR499a inhibitor, and then cell growth was measured. Both MTS and clone formation assay indicated that miR499a overexpression promoted cell proliferation of HCC cells ( Fig. 2A, B) . In contrast, the inhibition of miR499a suppressed cell proliferation (Fig. 2C, D) .
In order to further certify the role of miR499a in cell proliferation, the cells stably expressing miR499a (s-pmiR499a) or control cells expressing vector (s-pTarget) (Fig. 2E) were injected subcutaneously into the dorsal flank of nude mice. The tumor became palpable after implantation 7 days and all the mice developed tumors at the end of the experiment (Fig. 2F) . The tumor formed by miR499a-expressing cells showed increased tumor size and weight compared to control cells (Fig. 2G) . These results suggested that miR499a could promote cell proliferation in vivo.
MiR499a promoted migration of hepatoma cells
To determine whether miR499a was associated with migration of hepatoma cells, SMMC-7721 cells were transfected with pTarget or pTarget-miR499a and then wound healing assay was performed. As shown in Fig. 3A , miR499a overexpression group revealed an obvious increase in the cell migration ability relative to the control group. The result of transwell assay was in accordance with the result of wound healing assay (Fig. 3B) . In contrast, the inhibition of miR499a decreased cell migration ability (Fig. 3C ). These data indicated that miR499a could promote migration of hepatoma cells. 
MAPK6 was a target gene of miR499a
To determine putative miR499a targets, TargetScan and MiRanda bioinformatics algorithms were used. Software analysis revealed that MAPK6 might be a potential target of miR499a based on putative target sequences of MAPK6 mRNA 39UTR. Luciferase assay was performed to determine whether miR499a could directly target 39UTR of MAPK6 mRNA in SMMC-7721 cells. The target sequence of MAPK6 39UTR or mutant sequence was cloned into luciferase vector. Luciferase assay showed that miR449a suppressed the luciferase activity of 39UTR of MAPK6. (Fig. 4A ). In contrast, miR499a overexpression has no effect on luciferase activity of the mutant 39UTR reporter (Fig. 4A) .
Moreover, overexpression of miR499a significantly downregulated MAPK6 expression at both mRNA and protein levels in SMMC-7721 cells (Fig. 4B , C and D). On the contrary, inhibition of miR499a decreased both mRNA and protein of MAPK6 expressions (Fig. 4E , F and G). Together, these results indicated that MAPK6 was a target of miR499a.
HBV down-regulated the expression of MAPK6
Above results prompted us to examine whether HBV could regulate MAPK6 expression. Firstly, the expressions of MAPK6 were measured in HepG2 and HepG2.2.15 cells. As shown in Fig. 5A and B, the expressions of MAPK6 in HepG2 cells were higher than HepG2.2.215 cells at both mRNA and protein levels. Meanwhile, MAPK6 expression was significantly decreased in Ad-HBV infected cells in comparison with its control group (Fig. 5C , D). These results revealed that HBV could inhibit MAPK6 expression.
MiR499a promoted cell growth by reducing MAPK6
Accumulating evidence have demonstrated that the overexpression of MAPK6 lead to inhibition of cell proliferation [19] . MTS and colony formation assay were performed to analyze the effect of MAPK6 on cell proliferation of HCC cells. As shown in Fig. 6A , B and C, cell proliferation was markedly inhibited when MAPK6 overexpressed. In contrast, both MTS and colony formation assay showed the inhibition of MAPK6 could obviously promote cell growth (Fig. 6D, E and F) . Taken together, these data suggested that MAPK6 could suppress cell proliferation.
To explore whether miR499a promoted cell growth by targeting MAPK6, MTS was used to measure cell proliferation of SMMC-7721 cells cotransfected with pTarget-miR499a and pcDNA3.1-MAPK6. As shown in Fig. 6G , MAPK6 abolished the growth-promoting effect induced by miR499a. Furthermore, MAPK6 could also rescue HBV inducing cell growth (Fig. 6H ).
All the above data suggested that HBV or miR499a promoted proliferation of HCC cells probably through MAPK6.
Discussion
It is estimated there are more than 387 million HBV carriers and HBV infected people in the world. HBV was widely known as a high risk factor of HCC [20, 21] . In recent years, numerous studies have shown that miRNA play important roles in organisms physiological and pathological processes. In particular, tumorigenesis was highly related with negatively regulation of genes expression by miRNA, such as chronic lymphocytic leukemia, lung cancer, breast cancer and colon cancer. Several reports revealed that HBV infection could also alter the host miRNAs expression [22, 23] .
MiR499a were reported to be associated with variety of tumors [10, 24] . Li et al. have reported that miR499 regulated cell proliferation and apoptosis during late-stage cardiac differentiation via SOX6 and cyclinD1 [13] . However, the role of miR499a in HCC was not reported. So the main topic of our study is the influence of HBV on miR499a and the functions of miR499a in HCC. In our study, we firstly found HBV could up-regulate miR499a by promoting its promoter activity. In further research, our study firstly pointed out that miR499a could improve hepatoma cell proliferation in vitro and tumor growth in vivo, and revealed that miR499a could increase cell migration of hepatoma cells. Therefore, we suggested that miR499a might act as oncogene in HCC.
MAPK6 (ERK3) is an atypical member of the MAPK family, which can reduce cell proliferation through ERK3/ERK4-MK5 pathway [17] . In our research, we firstly demonstrated MAPK6 was a direct target gene of miR499a. Our results showed that miR499a increased cell proliferation via targeting MAPK6. The regulation of miRNA was a multi-targeted, multi-step and intricately network in cells. Therefore other genes might also be affected by miR499a and contribute to the increase of cell proliferation, which worth to be investigated.
Our results indicated HBV could up-regulate miR499a and promote cell growth partly by inhibiting MAPK6 expression. Meanwhile miR499a increases cell proliferation by down-regulating MAPK6 expression. These data suggested that HBV promoted cell proliferation, at least partly, by regulating miR499a and MAPK6 expression. However, whether HBV promoted the activity of miR499a promoter by modulated upstream transcription factor was not investigated. We found that miR499a could promote cell migration. However, MAPK6 had no effect on migration of HCC cells. So the mechanism of miR499a promote migration need further investigation. In summary, our findings thus provided a new perspective in understanding both the pleiotropic nature of miR499a and its contribution to HCC development. All the results suggested that miR499a might function as an onco-miRNA in HBV-related HCC. The pCMV-Sport6-HBx, pCMV-Sport6-HBs, pCMV-Sport6-HBc, and pCMV-Sport6-HBp plasmid were previously constructed in our laboratory and their correct expressions were confirmed in HepG2 cells (data not shown). The pGL3-Basic, pGL3-control and pRL-TK plasmids were purchased from Invitrogen (USA). The pTarget plasmid was purchased from Promega (USA). Ad-HBV adenovirus and its control Ad-GFP adenovirus were constructed by our laboratory.
Materials and Methods
Cell culture and Cell transfection
The miR499a promoter construct (pGL3-Basic-miR499a) was amplified with sequence (2950-+50) containing 50 bp miR499a precursor by using the following primers: forward (59-AGGTAC-CACAGCTAGTGAGTGAGGAAG-39); reverse (59-TCTCGA- GACTGCAAGTCTTAACAGCC-39). pTarget-miR499a, miR 499a expression plasmid, was constructed with fragment of miR499a precursor and the sequence was amplified by the following primers: forward (59-ACGACTCGAGCCCCATC-TTCCAGAAGTCAC-39); reverse (59-ATAAAGTC GACGC-AGCGGACGAAGTGGGCT-39). pGL3-control-MAPK6-wt was constructed by inserting part of the MAPK6 39UTR sequence containing putative miR499a binding site and amplified by the following primers: forward (59-CATCTAGACATGATACCAG-CAGCAAC-39); reverse (59-AATCTAGAAGTACGTGGA-CAGCCTTA-39). pGL3-control-MAPK6-mut was constructed by insert with the MAPK6 39UTR with point mutations in the seed sequence, which was amplified from the wild vector. The primers used were forward (59-ATGCTCCTAGAGCGTCA-GATTGTGTTTATTTTT-39); reverse (59-TAAACAC AATCT-GACGCTCTAGGA GCATTTTA-39). The full-length MAPK6 expression vector was built from MAPK6 mRNA using the following primers: forward (59-ACGGTACCAGGGTTTCA-AAATGGCAGAG-39); reverse (59-TCTCGAGTTAGTTCA-GATGTTTCAGAATGCTG-39) and cloned into pcDNA3.1, which was designated as pcDNA3.1-MAPK6. pTarget, pCMVsport6, pGL3-control, pGL3-Basic vectors were used as control. Ad-HBV adenovirus and its control Ad-GFP adenovirus were constructed by our laboratory as following steps: HBV 1.3 fold genome was ligated into shuttle vector pAdTrack-TO4, then pAdTrack-TO4-HBV1.3 was linearized by PmeI and transfected into BJ5183 cells containing pAd-Easy1 to form a recombinant plasmid. After that the confirmed recombinant plasmid was linearized by PacI restriction endonuclease and transfected into HEK-293 cells to generate recombinant adenoviruses [18] .
RNA interference
MiR499a inhibitor, inhibitor negative control (NC), siRNA duplexes target MAPK6 were synthesized and purified by Invitrogen (shanghai, China). SiRNA duplexes with non-specific sequences were used as siRNA negative control (NC). Different siRNAs were transfected separately into cells by using Lipofecatmine 2000 reagent.
Stable cell lines generation
The pTarget-miR499a plasmid or empty vector (pTarget) were transfected into the SMMC-7721 cells and selected with G418 (800 ug/ml) for 4 weeks. Then the stable cell lines called spmiR499a and s-pTarget were generated and cultured in medium with 400 mg/ml G418.
RNA isolation, reverse transcription, and quantitative real-time PCR
Total RNA of the cells was extracted with Trizol reagent (Invitrogen). In order to quantitate miR499a expression, miRNA cDNA Kit (CWBIO, China) and miRNA Real-Time PCR Assay Kit (CWBIO, China) were used. U6 was used as a miRNA internal control. To measure the mRNA expression of MAPK6, total RNA was reversely transcribed using the Reverse Transcription System (Promega, Madison, WI) and quantitative real time PCR was performed by using the UltraSYBR Mixture (CWBIO, China). bActin were used as an endogenous control. The primers were as follows: MAPK6-F (realtime) (59-ACTTGGTGCTGAAGATAG-39); MAPK6-R (realtime) (59-TGAGAAGCTCCTGACGAT-39); b-Actin-F (59-CCTTCTACAAATGAGCTGCGT-39); b-Actin-R (59-CCTGGATAGCAACGTA CATG-39). All samples were normalized to internal controls and fold changes were calculated through relative quantification (2 2DDct ).
Western blot
For protein extraction, cells were homogenized on ice in RIPA buffer (Beyotime, China) with PMSF (Beyotime, China) and cellular debris was pelleted at 12,000 g for 30 min at 4uC. Protein was quantified by using enhanced BCA Protein Assay Kit (Beyotime, China) and separated by 8% sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE), and then transferred to PVDF membranes followed by blocking with 5% non-fat milk. The membranes were incubated with primary antibody against MAPK6 pAb (Bioworld, China), followed by HRP-conjugated secondary antibody (goat anti-rabbit antibody and goat anti-mouse antibody, ZSGB-BIO, China). The membranes were then washed and detection was performed by using the enhanced chemiluminescence western blot detection system (Millipore, USA). Images of each band were analyzed by Bio-Rad Gel Imaging System and normalized to b-actin mAb (Beijing Com Win Biotech Co. Ltd, China). Representative images of three independent experiments are shown in the results section.
Luciferase assay
In order to assay the effect of HBV on miR499a promoter, the pCH9/3091, pCMV-Sport6-HBx, pCMV-Sport6-HBs, pCMVSport6-HBc, and pCMV-Sport6-HBp plasmids were relatively cotransfected with pGL3-Basic-miR499a and pRL-TK into SMMC-7721 cells. In order to assay the effect of miR499a on the 39UTR of MAPK6, SMMC-7721 cells were cotransfected with pGL3-control-MAPK6-wt or pGL3-control-MAPK6-mut and pTarget-miR499a. Each sample was also cotransfected with pRL-TK. Cells were harvested 48 h later and assayed with the Dualluciferase Reporter Assay System (Promega, Madison, WI). Relative luciferase activity was normalized to renilla luciferase activity. Transfections were done in duplicate and repeated at least 3 times in independent experiments.
Cell proliferation assay and colony formation assay
After 24 h of transfection, cells were trypsinized and plated into 96-well plates (8000 per well). At different time points (12 h, 24 h, 48 h), cells were determined by using the MTS kits (Promega, WI, USA) following the manufacturer's protocol and the absorption was read at 490 nm. For colony formation assay, cells were trypsinized and plated in 6-well plates (2000 per well) after transfected for 24 h. Colonies were counted 14 days later using Crystal violet fixed.
Analysis of tumorigenicity in nude mice
This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Committee on the Ethics of Animal Experiments of the Chongqing Medical University. All surgery was performed under sodium pentobarbital anesthesia, and all efforts were made to minimize suffering. Male BALB/c nude mouse mice aged 4 weeks were used for human tumor xenograft model (supplied by the Chongqing Medical University Animal Center, chongqing, China). s-pTarget or s-pmiR499a cells (5610 6 ) were mixing in 200 ml MEM medium and then injected subcutaneously into the posterior flank of nude mice respectively. Tumor growth was examined every week. Tumor volume (V) was monitored by measuring the length (L) and width (W) with calipers and calculated with the formula (L6W)60.5.
Wound healing assay
SMMC-7721 cells transfected with pTarget or pTargetmiR499a were seeded in 2 ml of RPMI 1640 medium without fetal bovine serum. After 12 h, cells were wounded by dragging a 200 ml pipette tip through the monolayer. PBS was used to wash cellular debris for 3 times and cells were cultured in RPMI 1640 medium with 2% fetal bovine serum. Cell migration images were photographed by using microscope when the scrape wound was introduced (0 h) and at a designated time 24 h and 48 h. The dividing the length of the gap by the culture time showed the speed of migration. Three replicates each of two independent experiments were performed
Transwell assay
The migration ability of the cells was assessed using Transwell Chambers (8 mm pore size; Millipore). SMMC-7721 cells were severally transfected with pTarget, pTarget-miR499a, NC, miR499a inhibitor, pCH9 or pCH9/3091. After 24 h transfection, cells were resuspended in 5% serum medium. 200 ml of the single-cell suspension (1610 4 , per well) was seeded onto the upper chamber of each transwell, and the lower 24-well chamber was filled with 600 ml of the cell culture medium supplemented with 10% FBS as a chemoattractant. A sterile cotton swab was used to remove the cells that did not migrate from the upper surface of the membranes. The membranes were fixed with 4% formaldehyde and stained with 0.05% crystal violet. Then the cells adhered to the lower surface of the membranes were photographed and counted by using microscope(1006) in three randomly selected areas per well.
Statistical analysis
All the data which was expressed as the mean 6 SD was repeated at least thrice. T test was used for analyzed the difference between the control and experimental test. The value of p,0.05 was considered statistically significant. Figure S1 RT-PCR analysis of HBV four expression plasmid in HepG2 cells. pCMV-Sport6-HBx, pCMV-Sport6-HBs, pCMV-Sport6-HBc and pCMV-Sport6-HBp were transferred into HepG2 cells, respectively. Then RNAs were extracted, digested with DNase I and reverse transcripted into cDNAs. 
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